Detalles de la búsqueda
1.
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
J Immunother Cancer
; 11(11)2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38016718
Resultados
1 -
1
de 1
1
Próxima >
>>